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ORIGINAL RESEARCH
SMIT (Sodium-Myo-Inositol Transporter) 1 
Regulates Arterial Contractility Through the 
Modulation of Vascular Kv7 Channels
Vincenzo Barrese , Jennifer B. Stott, Samuel N. Baldwin , Gema Mondejar-Parreño , Iain A. Greenwood
OBJECTIVE: The SMIT1 (sodium:myo-inositol transporter 1) regulates myo-inositol movement into cells and responses to 
hypertonic stimuli. Alteration of myo-inositol levels has been associated with several diseases, including hypertension, but 
there is no evidence of a functional role of SMIT1 in the vasculature. Recent evidence showed that in the nervous system 
SMIT1 interacted and modulated the function of members of the Kv7 family of voltage-gated potassium channels, which 
are also expressed in the vasculature where they regulate arterial contractility. Therefore, in this study, we evaluated whether 
SMIT1 was functionally relevant in arterial smooth muscle. 
APPROACH AND RESULTS: Immunofluorescence and polymerase chain reaction experiments revealed that SMIT1 was expressed 
in rat renal and mesenteric vascular smooth muscle cells. Isometric tension recordings showed that incubation of renal arteries 
with raffinose and myo-inositol (which increases SMIT1 expression) reduced the contractile responses to methoxamine, an 
effect that was abolished by preincubation with the pan-Kv7 blocker linopirdine and by molecular knockdown of Kv7.4 and 
Kv7.5. Knockdown of SMIT1 increased the contraction of renal arteries induced by methoxamine, impaired the response to 
the Kv7.2–Kv7.5 activator ML213 but did not interfere with the relaxant responses induced by openers of other potassium 
channels. Proximity ligation assay showed that SMIT1 interacted with heteromeric channels formed by Kv7.4 and Kv7.5 
channels in both renal and mesenteric vascular smooth muscle cells. Patch-clamp experiments showed that incubation with 
raffinose plus myo-inositol increased Kv7 currents in vascular smooth muscle cells.
CONCLUSIONS: SMIT1 protein is expressed in vascular smooth muscle cells where it modulates arterial contractility through an 
association with Kv7.4/Kv7.5 heteromers.
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The cyclic polyol myo-inositol is an organic osmo-lyte that plays a pivotal role in many cell types, regulating their response to hypertonic environ-
ments. Intracellular levels of myo-inositol are tightly 
controlled by the activity of membrane transporters 
belonging to the SLC5A (solute carrier family 5A) that 
mediate the influx of substrates along with sodium. 
Two SMIT (sodium:myo-inositol transporter) have been 
cloned and named SMIT1 (SLC5A3)1 and SMIT2 
(SLC5A11).2 Because their first identification in the 
kidney, myo-inositol transporters have been found in 
several other tissues including the brain, liver, pancreas, 
placenta, heart and skeletal muscle.3,4 Expression of 
SMIT1 is upregulated by extracellular hypertonicity 
via transcriptional mechanisms, resulting in enhanced 
uptake of myo-inositol by cells. This prevents an 
increase in the concentration of inorganic ions with-
out perturbing the activity of macromolecules.5 Altera-
tions of SMIT1 function have been associated with 
several diseases, including Down syndrome, Alzheimer 
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disease, and mood disorders.6 Moreover, alterations 
of myo-inositol metabolism have been observed in 
other diseases, such as epilepsy,7,8 stroke,9 and diabe-
tes mellitus.10 Administration of myo-inositol has been 
proposed as a potential therapeutic strategy in these 
conditions.
In addition to its osmotic role, myo-inositol is a sub-
strate for the biosynthesis of phosphatidylinositol, a 
membrane molecule that is the precursor of phospha-
tidylinositol-4,5-bisphosphate (PIP2), a key modulator of 
many ion channels.6,11 Consequently, myo-inositol trans-
porters may have a profound effect on ion channel activ-
ity. Regulation of ion channels function in the vasculature, 
in particular, K+ channels, is a key mechanism modulating 
arterial contractility.
KCNQ-encoded potassium channels (Kv7.1–7.5) 
are important regulators of cellular activity in neurons, 
cardiac myocytes, epithelia, and smooth muscle cells, 
which have an exquisite reliance upon local PIP2 lev-
els.12 Within the vasculature, Kv7.1, Kv7.4, and Kv7.5 
are the main subunit expressed, have been shown to 
regulate arterial contractility at rest, and contribute to 
receptor-mediated vasorelaxation.12,13 Recently, SMIT1 
has been shown to interact with Kv7.1, Kv7.2, and 
Kv7.3 resulting in increased activity of the channels.8,14 
These chansporter complexes15 have been implicated 
as key determinants of neuronal activity,8,16,17 suggest-
ing a tight link between regulation of osmolarity and 
cell excitability. Acute exposure to hypertonic solution 
causes vasodilation in several arterial beds includ-
ing skeletal muscle arterioles, mesenteric and coro-
nary arteries, through poorly defined mechanisms.18–20 
Moreover, increased urinary depletion of myo-inositol 
has been observed in diabetic patients and in animal 
models of metabolic diseases including hyperten-
sion.21,22 However, there is little data about the expres-
sion of myo-inositol transporters in the arteries,23 and 
there is no evidence about their functional role in vas-
cular smooth muscle cells (VSMCs). We, therefore, set 
out to establish expression of SMIT1 in VSMCs and 
ascertaining if modifying SMIT1 levels altered arterial 
contractility potentially through an interaction with Kv7 
channels.
MATERIALS AND METHODS
Please see the Major Resources Table in the Data Supplement. 
Detailed methods are available in the Data Supplement. The 
authors declare that all supporting data are available within the 
article (and its Data Supplement files).
Arteries
Main conduit renal and third-order mesenteric arteries were 
microdissected and cleaned of adherent fat in ice-cold Krebs 
solution, as previously described.24 Arteries were incubated in 
DMEM/F-12 culture medium (Sigma Aldrich, Dorset, United 
Kingdom) supplemented with 1% penicillin-streptomycin (Sigma 
Aldrich, Dorset, United Kingdom) in a 37°C incubator with 5% 
CO2 for 16 hours (for myo-inositol/raffinose treatments) or 48 
hours (for gene-silencing experiments). In double knockdown 
experiments, arteries were incubated in the morpholinos trans-
fection mix for 32 hours and then incubated in medium contain-
ing either vehicle or raffinose plus myo-inositol for 16 hours.
Cell Culture
Chinese Hamster Ovary (CHO) cells were maintained in DMEM 
supplemented with 10% (v/v) FBS, 2 mmol/L L-glutamine, and 
1% (v/v) penicillin/streptomycin (Sigma Aldrich, Dorset, United 
Kingdom) in a 37°C incubator with 5% CO2. CHO cells were 
plated in 6-well dish and transfected with pcDNA3.1-KCNQ4, 
pcDNA3.1-KCNQ5, pcDNA3.1-SMIT1, and pGFP (pMax-
CloningTM Vector, Lonza, Basel, Switzerland) plasmids using 
Lipofectamine 2000 (Thermo Fisher, Paisley, United Kingdom), 
according to the manufacturer’s instructions. CHO cells were 
used 24 hours after transfection.
Isolation of Vascular Smooth Muscle Cells
VSMCs were isolated as previously described.24 Arteries were 
digested with collagenase type IA (2 mg/mL) and protease 
type X (1 mg/mL). For quantitative polymerase chain reaction 
(PCR) experiments, VSMCs were prepared to ensure removal 
of endothelium as previously described.25
Gene Knockdown
Knockdown of Kv7.4, Kv7.5, and SMIT1 in renal and mesenteric 
arteries was performed by transfection with morpholino oligo-
nucleotides as described in vessels previously.26 Targeting and 
scrambled (control) morpholino oligonucleotides (5 µmol/L; 
Genetools, Oregon) were mixed in Opti-MEM and transfected 
using Lipofectamine 2000 (Thermo Fisher, Paisley, United 
Kingdom).
Nonstandard Abbreviation and Acronyms
CHO Chinese hamster ovary
PIP2 phosphatidylinositol-4,5-bisphosphate
SLC5A solute carrier family 5A
SMIT1 sodium:myo-inositol transporter 1
TonEBP  tonicity responsive enhancers binding 
protein
TRPC1 transient receptor potential C1 channel
VSMC vascular smooth muscle cells
Highlights
• The myo-inositol transporter SMIT1 (sodium:myo-
inositol transporter 1) modulates arterial contractility.
• SMIT1 interacts with Kv7.4/Kv7.5 heteromeric chan-
nels in the vasculature and affect their function.
• This is the first evidence of the interaction of a trans-
porter with a K+ channel in the vasculature.
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RNA Extraction, Reverse Transcription and 
Quantitative PCR
Total RNA was extracted from arteries using Monarch Total 
RNA Miniprep Kit (New England Biolabs, Hitchin, United 
Kingdom), according to the manufacturer’s instruction, and 
reverse transcribed to cDNA using Luna Script RT Super Mix 
((New England Biolabs, Hitchin, United Kingdom). Quantitative 
PCR experiments were run in CFX96 Real-Time PCR Detection 
System (Bio-Rad, Hertfordshire, United Kingdom) using the 
SYBR-Green detection technique and specific primers (Table I 
in the Data Supplement), as previously described.24
Immunofluorescence
VSMCs were fixed with 3% paraformaldehyde, treated with 0.1 
mol/L glycine, and incubated with primary antibodies overnight 
at 4°C, as previously described.16 Coverslips were then washed 
with PBS and incubated for 1 hour with secondary antibodies 
conjugated to Alexa Fluor 488 or Alexa Fluor 567. Coverslips 
were analyzed with a Nikon A1R confocal microscope (Nikon 
Instruments Europe BV, Amsterdam, Netherlands). Corrected 
total cell fluorescence was calculated using ImageJ software 
as elsewhere described.27 The number of cells analyzed is indi-
cated by n, whereas N represents the number of animals used.
Patch-Clamp Recordings
All current recordings were made with an Axopatch 200B and 
a Digidata 1322A (Axon Instruments, Burlingame, CA). For 
renal VSMCs, membrane Kv currents were measured using 
perforated whole-cell voltage-clamp by including amphotericin 
B in the pipette solution (final concentration of 200 µg/mL) at 
room temperature (21ºC–23ºC).
Wire Myography
Segments of renal arteries (≈2 mm) were mounted in a wire 
myograph (Danish Myo Technology, Aarhus, Denmark) for iso-
metric tension recording. Concentration-effect curves for meth-
oxamine (30 nmol/L–30 µmol/L) or KCl (10–120 mmol/L) 
were constructed to evaluate arterial contractility after the 
experimental treatments. Data were recorded and analyzed 
using LabChart 7 (ADInstruments, Dunedin, New Zealand).
Proximity Ligation Assay
Proximity ligation assay (PLA) was used to assess protein-pro-
tein interactions as previously described using validated anti-
bodies.24,26 Analysis of midcell xy sections was performed using 
ImageJ software. For PLA in CHO cells, the number of puncta 
per cell was calculated by dividing the total number of dots by 
the number of nuclei in the microscopic field.
Drugs
Specific activators of different potassium channels were used 
at submaximal concentrations derived from previous work. 
These were the Kv7.2–7.5 activators ML213 and retigabine29 
(Tocris Bioscience, Bristol, United Kingdom), the Kv7.1 acti-
vator RL-330 (Sigma Aldrich, Dorset, United Kingdom), the 
KATP activator levcromakalim
31 (Tocris Bioscience, Bristol, 
United Kingdom), and the BKCa activator NS11021
32 (Tocris 
Bioscience, Bristol, United Kingdom). Specific blockers of Kv7 
channels (XE991,24 linopirdine and HMR155633), SMIT1 (phlo-
rizin8), and the G-protein-gated inwardly rectifying K+ channels 
(Tertiapin Q34) were purchased from Tocris Bioscience, Bristol, 
United Kingdom.
Statistical Analysis
All data are expressed as mean±SEM. One- or 2-way ANOVA 
test followed by a Bonferroni, Dunnett, or Tukey multiple com-
parisons test, and Student t test (paired or unpaired) were used 
to determine statistical significance between groups, according 
to the different experiments. The significance level for statistic 
tests was 0.05 (differences were considered statistically sig-
nificant when P<0.05).
RESULTS
SMIT1 Is Expressed in Rat VSMCs
Immunofluorescence experiments on freshly dispersed arte-
rial VSMCs isolated from rat renal and mesenteric arteries 
were performed to determine whether SMIT1 was present 
in vascular smooth muscle cells. Images in Figure 1A show 
that SMIT1 was expressed in renal and mesenteric VSMCs, 
with a predominantly peripheral, membrane-like distribu-
tion. Quantitative PCR in purified renal VSMCs showed an 
abundant expression of SMIT1 (slc5a3), whereas levels of 
SMIT2 (slc5a11) were negligible (Figure 1B).
Modulation of SMIT1 Levels Regulates Arterial 
Contractility
Renal arteries were incubated overnight with different 
treatments known to potentiate or reduce SMIT1 function 
and expression,17 and vascular reactivity was evaluated 
by measuring contractions to increasing concentration of 
the α1-adrenergic receptors agonist methoxamine (30 
nmol/L–30 µmol/L). Incubation of renal arteries with 
a SMIT1-specific morpholino oligonucleotide reduced 
SMIT1 expression by ≈40% (Figure 2A, left) and pro-
duced a right-shift in the concentration-response curve 
for methoxamine with respect to control (at 1 µmol/L 
methoxamine: 40±8% of maximal contraction with 
SMIT1-morpholino; 14±5% for scrambled control; Fig-
ure 2A, right). Neither 3-hour nor 16-hour (overnight) 
incubation with the SMIT1 transport inhibitor phlorizin 
(500 µmol/L) modified methoxamine-induced contrac-
tion of renal artery (Figure I in the Data Supplement).
Previous studies showed that SMIT1 abundance in 
neuronal cell membranes is increased by bathing solu-
tions made hypertonic by addition of raffinose.17,23 Over-
night incubation of renal arteries with 150 mmol/L 
raffinose plus the transporter substrate myo-inositol 
(1 mmol/L) increased SMIT1 fluorescence intensity in 
VSMCs by ≈140% with respect to controls (Figure 2B, 
left) and reduced concentration-dependent contractions 
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to methoxamine (at 1 µmol/L methoxamine: 10±3% 
of maximal contraction with raffinose plus myo-inositol; 
39±10% for control; Figure 2B). Incubation with raffi-
nose alone also inhibited contractions to methoxamine, 
although to a lesser extent as raffinose plus myo-inositol 
(at 1 µmol/L methoxamine: 20±7% of maximal contrac-
tion; Figure 2B). In contrast, overnight incubation with 
myo-inositol alone did not affect renal artery contractility. 
Addition of the SMIT1 transport inhibitor phlorizin (500 
µmol/L) had a small effect on the anticontractile action of 
raffinose plus inositol (Figure IIA in the Data Supplement). 
Moreover, wortmannin (10 nmol/L), that depletes PIP2 lev-
els, partially prevented the right-shift of the concentration-
response curve to methoxamine induced by raffinose plus 
myo-inositol, being effective only at 3 µmol/L methox-
amine (82±4% of maximal contraction in wortmannin and 
raffinose plus myo-inositol; 54±12% in raffinose+myo-
inositol; Figure IIB in the Data Supplement).
Incubation or renal arteries with raffinose plus myo-
inositol did not modify the contractile response induced 
by 60 mmol/L KCl (Figure 1C, left). When exposed to 
increasing concentration of KCl (10–120 mmol/L), incu-
bation of renal arteries with raffinose plus myo-inositol 
caused a reduction of the contraction only at lower KCl 
concentration with respect to controls (at 40 mmol/L 
KCl: 46±7 of maximal contraction with raffinose plus 
myo-inositol; 80±11% in control), a result consistent 
with the involvement of K+ channels in mediating the 
effects on arterial contractility induced by raffinose plus 
myo-inositol (Figure 2C, right).
Overall, these results show that augmenting mem-
brane expression of SMIT1 attenuated vasoconstrictor 
responses with a mechanism that was partly dependent 
on increased intracellular availability of myo-inositol.
SMIT1 Selectively Modulates the Functional 
Impact of Specific Kv7 Subunits
Having established that SMIT1 modulates arterial con-
tractility, we investigated whether these effects occurred 
through the regulation of the activity of K+ channels, which 
are key regulators of arterial contractility. To this aim, we 
evaluated whether modulating SMIT1 levels interfered 
with the ability of several activators of different K+ chan-
nel classes found in the vasculature to counteract the 
vasoconstriction of renal artery segments induced by 10 
µmol/L methoxamine (Figure 3A). Under control condi-
tions methoxamine-induced contractions were reduced 
by preincubation with the Kv7.2–Kv7.5 activator ML213 
(3 µmol/L; 24±3% of first contraction to methoxamine), 
the Kv7.1-specific activator RL-3 (3 µmol/L; 65±13%), 
the KATP- opener levcromakalim (3 µmol/L; 57±18%), 
and the BKCa activator NS11021 (3 µmol/L; 84±2%; 
Figure 3B through 3E, black bars). Knockdown of SMIT1 
caused a significant impairment of the ML213 effect on 
methoxamine-induced contraction (49±7% of first con-
traction to methoxamine, Figure 3B, white bars), whereas 
no changes were observed in the responses to the other 
K+ channels activators (RL-3: 75±10%; LEV: 67±12%; 
NS11021: 83±11%; Figure 3C through 3E, white bars). 
Figure 1. Expression of SMIT1 (sodium:myo-inositol transporter 1) in vascular smooth muscle cells (VSMCs).
A, Representative immunofluorescence showing the expression of SMIT1 protein in VSMCs isolated from renal arteries (RA, top) and 
mesenteric arteries (MA, bottom). The right-most parts show the staining in absence of the SMIT1 antibody (No I Ab). The insets show 
a brightfield image of the cell. Nuclei (DAPI staining, blue) are also shown. Scale bar=10 µm (left-most parts) and 5 µm (other parts). B, 
Quantitative polymerase chain reaction showing the expression of the transcripts encoding for Kv7.4 (kcnq4), Kv7.5 (kcnq5), SMIT1 (slc5a 
[solute carrier family 5A] 3) and SMIT2 (slc5a11) in VSMCs isolated from renal arteries. Data are expressed using the 2-ΔCq formula (N=5).
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Figure 2. Effects of the modulation of SMIT1 (sodium:myo-inositol transporter 1) levels on arterial contractility.
A, left, representative images showing the immunostaining of SMIT1 in renal vascular smooth muscle cells (VSMCs) incubated with a 
scrambled (CTL-mor) or an anti-SMIT1 morpholino oligonucleotide (SMIT1-mor). The insets show brightfield images of the cells. Scale bar=5 
µm. The graph shows the quantification of SMIT1 fluorescence intensities measured as corrected total cell fluorescence (CTCF) and expressed 
as percentage of control (CTL-mor). Data are expressed as mean±SEM. *P<0.05 vs respective controls; n=28 cells for CTL-mor and 30 
cells for SMIT1-mor obtained from 3 different preparations (N=3). Right, isometric tension recordings showing the effects of increasing 
concentration of methoxamine (MO) in segments of renal arteries after 48 h incubation with CTL-mor (black line) or SMIT1-mor (red line). Data 
are shown as percentage of the contraction obtained with 30 µmol/L MO. Data are expressed as mean±SEM. ***P<0.001; ****P<0.0001 
vs controls; N=13 for CTL-mor and 16 for SMIT1-mor. B, left, representative images showing the immunostaining of SMIT1 in renal VSMCs 
incubated with vehicle (CTL) or raffinose plus myo-inositol (R+M). The insets show brightfield images of the cells. Scale bar=5 µm. The graph 
shows the quantification of SMIT1 fluorescence intensities measured as CTCF and expressed as percentage of control. Data are expressed 
as mean±SEM. *P<0.05 vs respective controls; n=28 cells for CTL and 30 cells for R+M from 3 different preparations (N=3) per experimental 
group. Right, isometric tension recordings showing the effects of increasing concentration of MO in segments of renal arteries after 16 h 
incubation with vehicle (control, black line, N=10), 1 mmol/L myo-inositol (M, green line, N=6), 150 mmol/L raffinose (R, blue line; N=8), or 150 
mmol/L raffinose plus 1 mmol/L myo-inositol (R+M, red line, N=10). Data are shown as percentage of the contraction obtained with 30 µmol/L 
MO. Data are expressed as mean±SEM. *P<0.05; **P<0.01; ***P<0.001; ****P<0.0001 vs controls. (Continued )
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In contrast to the knockdown studies, increasing SMIT1 
levels by incubation with raffinose and myo-inositol did 
not alter the vasorelaxant properties of any of the selected 
K+ channels openers when compared with their respec-
tive controls (Figure III in the Data Supplement). To further 
investigate the possible involvement of Kv7 channels in the 
anticontractile effect of SMIT1, we performed myography 
experiments with the pan-Kv7 blocker linopirdine. Applica-
tion of linopirdine (1–3 µmol/L) contracted renal arteries 
considerably less in segments incubated with raffinose and 
myo-inositol (Figure 4A) and abrogated the reduced con-
traction to methoxamine produced by treatment with raf-
finose and myo-inositol (Figure 4B). Similar effects were 
not seen with the selective Kv7.1 blocker HMR1556 (1 
µmol/L; Figure 4B) nor tertiapin Q (1 µmol/L), a blocker of 
the inward-rectifier K+ channel GIRK (Figure IV in the Data 
Supplement).
To further investigate the involvement of Kv7.4 and 
Kv7.5 channels in mediating the effects of SMIT1 on 
arterial contractility, we reduced Kv7.4 and Kv7.5 chan-
nels levels with morpholino oligonucleotides (Q4/
Q5-mor). Knockdown of Kv7.4 and Kv7.5 prevented the 
rightward-shift of the concentration-response curves for 
methoxamine and KCl (Figure 5A and 5B) induced by 
incubation with raffinose plus myo-inositol. The effective 
knockdown of Kv7.4 and Kv7.5 channels was confirmed 
by the lack of vasorelaxant effects of the Kv7 activator 
retigabine (10 µmol/L) in arteries transfected with mor-
pholinos targeting Kv7.4 and Kv7.5 (Figure 5C). Overall, 
these data show that SMIT1 influences vascular contrac-
tility via a mechanism dependent, in part, on Kv7.4/Kv7.5.
SMIT1 Interacts With Heteromeric Kv7.4–Kv7.5 
Channels
Our myography data suggests that SMIT1 modulates vas-
cular reactivity through altering Kv7 channel activity. The 
impairment of the ML213-dependent relaxation in SMIT1-
silenced arteries and the lack of effect of the Kv7.1-selec-
tive drugs (RL-3, HMR1556), along with the impairment of 
raffinose plus myo-inositol effects in Kv7.4/Kv7.5–silenced 
arteries suggest the involvement of Kv7.4 and Kv7.5 sub-
units. Therefore, we performed PLA to investigate whether 
SMIT1 interacted with Kv7 channel subunits. PLA puncta 
were detected in VSMCs from renal and mesenteric 
arteries for both Kv7.4-SMIT1 and Kv7.5-SMIT1 couples 
(Figure 6A). Interestingly, SMIT1 also interacted with the 
ancillary KCNE4 subunit that is abundant in VSMCs and 
colocalizes with Kv7.4/Kv7.5 channels35 (Figure VA in the 
Data Supplement). To get insight into the dynamic changes 
of these interactions when SMIT1 expression was upregu-
lated, we evaluated the PLA puncta for Kv7.4-SMIT1 and 
Kv7.5-SMIT1 in renal arteries incubated with raffinose plus 
myo-inositol. Enhancing SMIT1 expression increased the 
number of PLA puncta for Kv7.4-SMIT1 and Kv7.5-SMIT1 
by ≈60 and ≈85%, respectively. Treatment with raffinose 
plus myo-inositol did not modify the interaction of SMIT1 
with the voltage-gated K+ channel Kv2.1 or the interac-
tion of Kv7.4 or Kv7.5 with the TRPC1 (transient receptor 
potential C1 channel; Figure 6B), suggesting a preferential 
interaction between SMIT1 and Kv7.4/Kv7.5 channels in 
these experimental settings.
We then performed further experiments to evaluate 
the molecular determinant of the interaction between 
SMIT1 and Kv7 channels by analyzing the PLA puncta 
for Kv7.4-SMIT1 and Kv7.5-SMIT1 when Kv7 subunits 
were knocked down with morpholino oligonucleotides. As 
shown in Figure 6C, morpholino targeting Kv7.4 (Q4-mor) 
reduced the number of interactions of SMIT1 with Kv7.4 
(≈60%) and Kv7.5 (≈50%) in renal arteries. Similarly, a 
morpholino targeted to Kv7.5 (Q5-mor) reduced SMIT1-
Kv7.4 and SMIT1-Kv7.5 interactions by ≈50%. Both mor-
pholinos reduced the number of PLA punctae observed 
when antibodies for Kv7.4 and Kv7.5 were used with 
respect to control condition (Figure 6C). Similar results 
were observed in VSMCs isolated from mesenteric arteries 
(Figure VB in the Data Supplement). To get further insight 
into the stoichiometry of these interactions, we performed 
PLAs on CHO cells overexpressing homomeric Kv7.4 
or Kv7.5 channels and heteromeric channels formed by 
Kv7.4 and Kv7.5. Although PLA signals were detected for 
Kv7.5-SMIT1 in CHO cells transfected with Kv7.5 only, the 
number of Kv7.4-SMIT1 interactions in CHO transfected 
with Kv7.4 was not significantly different from background 
signals. Interestingly, a significant increase in PLA puncta 
for Kv7.4 and SMIT1 was detected when Kv7.4 and Kv7.5 
were c-expressed in CHO cells (Figure VC in the Data 
Supplement). These results suggest that SMIT1 interacts 
with heteromeric channels formed by Kv7.4 and Kv7.5.
SMIT1 Effects on Kv7-Mediated Currents
In studies on CHO cells, the amplitude of currents pro-
duced by the overexpression of Kv7.4 and Kv7.5 was not 
altered by coexpression with SMIT1 (Figure 7A), but 
there was a small but nonsignificant effect on the volt-
age-dependence of activation (V1/2=−10.6±4.0 mV for 
Kv7.4/7.5; V1/2=−16.1±3.4 for Kv7.4/7.5 plus SMIT1; n=8 
per group; P=0.32). In studies on native K+ currents in iso-
lated renal artery smooth muscle cells, increasing SMIT1 
Figure 2 Continued. C, left, isometric tension recordings showing the effects of 60 mmol/L KCl in renal arteries after 16 h incubation with 
vehicle (control, black bars, N=20), or 150 mmol/L raffinose plus 1 mmol/L myo-inositol (R+M, red bars, N=22). Arteries were challenged with 
2 independent KCl stimuli. Right, Isometric tension recordings showing the effects of increasing concentration of KCl in segments of renal 
arteries after 16 h incubation with vehicle (control, black line) or 150 mmol/L raffinose plus 1 mmol/L myo-inositol (R+M, red line). Data are 
shown as percentage of the contraction obtained with 120 mmol/L KCl. Data are expressed as mean±SEM. ***P<0.001; ****P<0.0001 vs 
controls; N=6 per experimental group.
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expression by overnight incubation of the artery in raf-
finose plus inositol increased XE991-sensitive currents 
compared with control (Figure 7B and 7C). Raffinose plus 
inositol had no effect on the membrane capacitance (raffi-
nose plus myo-inositol: 33±1.4 pF; control: 36.0±2.8 pF).
These results show that in identical recording con-
ditions augmenting SMIT1 increased Kv7 currents in 
VSMCs.
DISCUSSION
SMIT1 Regulates Arterial Contractility
In this study, we identified that SMIT1 mRNA and 
protein are expressed in VSMCs, and altering SMIT1 
levels regulated arterial contractility mainly through the 
modulation of Kv7 channels. Introduction of a morpho-
lino targeting SMIT1 reduced SMIT1 abundance and 
enhanced vasoconstrictor responses, whereas exposure 
to hypertonic medium that increased SMIT1 expression 
reduced arterial contractility. These data provide the 
first evidence that SMIT1 protein is expressed in the 
vasculature and has a functional role in the regulation 
of arterial contractility.
Our results show that methoxamine in raffinose-incu-
bated arteries was less effective compared to arteries 
incubated in isotonic conditions. These effects were not 
due to a direct effect of the hypertonicity produced by raf-
finose because acute application had no relaxant effect 
and the inhibitory effect was maintained after bathing 
Figure 3. Effects of SMIT1 (sodium:myo-inositol transporter 1)-silencing on K+ channels activators.
A, Representative image showing the protocol used for isometric tension recordings. After 2 stimulations with 10 µmol/L methoxamine (MO), 
segments of renal arteries were incubated for 10 min with K+ channels activators (all used at a concentration of 3 µmol/L) and then stimulated 
again with MO. B–E, Quantification of the responses to MO in the presence of ML213 (B, N=9), RL-3 (C, N=6), levcromakalim (D, N=5), or 
NS11021 (E, N=4) in renal arteries incubated with a scrambled (CTL-mor) or an anti-SMIT1 morpholino oligonucleotide (SMIT1-mor). Data are 
expressed as mean±SEM. and shown as percentage of the contraction to the first stimulation with MO (see A). The responses to the second 
incubation of MO before the incubation with the activators (MO) are also shown. **P<0.01.
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in isotonic medium for over an hour. We speculated this 
might be due to increased SMIT1 activity as raffinose 
(and hyperosmolarity in general) induces the activity 
of the transcription factor TonEBP (tonicity responsive 
enhancers binding protein) that increases the expression 
of SMIT1.5 Consistent with this hypothesis, we observed 
greater membrane abundance of SMIT1 in renal artery 
smooth muscle cells following incubation with raffinose 
plus myo-inositol similar to previous reports in neurons.17 
Further support for a direct role of SMIT1 in the regulation 
of vascular contractility was provided by the observation 
that SMIT1-silenced arteries were significantly more 
contractile than control arteries. Consequently, there is 
a correlation between changes in SMIT1 abundance and 
Figure 5. Effects of enhanced SMIT1 (sodium:myo-inositol 
transporter 1) expression and silencing of Kv7.4 and Kv7.5 in 
renal arteries.
Isometric tension recordings showing the effects of increasing 
concentration of methoxamine (MO, A) or KCl (B) in segments of 
renal arteries transfected with a scrambled morpholino (CTL-mor) 
or 2 morpholinos targeting Kv7.4 and Kv7.5 (Q4/Q5-mor). 32 h 
after the transfection, arteries were incubated for 16 h with either 
vehicle (black and gray lines) or 150 mmol/L raffinose plus 1 mmol/L 
myo-inositol (raffinose plus myo-inositol [R+M]; red and orange 
lines). Data are shown as percentage of the contraction obtained 
with 30 µmol/L MO (A) or 120 mmol/L KCl (B). Data are expressed 
as mean±SEM. *P<0.05; **P<0.01: ****P<0.0001 vs CTL-mor 
vehicle; ###P<0.001; ####P<0.0001 vs Q4/Q5-mor R+M; N=6 
for vehicle incubated arteries and 8 for Q4/Q5-mor arteries. C, Bar 
graph showing the effects of the Kv7 activator retigabine (RET) in 
Kv7.4 and Kv7.5-silenced arteries. At the end of the experiments 
shown in A and B, arteries were challenged twice with 10 µmol/L 
MO alone (second MO contraction is shown with black bars) and 
then with MO in the presence of 10 µmol/L RET (white bars). Data 
are expressed as mean±SEM and shown as percentage of the 
contraction to the first stimulation with MO. ****P<0.0001; N=6 for 
vehicle incubated arteries and 8 for Q4/Q5-mor arteries.
Figure 4. Effects of enhanced SMIT1 (sodium:myo-inositol 
transporter 1) expression on Kv7 channels blockers.
A, top, representative traces showing the effects on isometric 
tension recordings of the pan-Kv7 blocker linopirdine (3 µmol/L) 
in renal arteries after 16 h incubation with vehicle (black line) or 
raffinose plus myo-inositol (R+M; gray line). Bottom, bar graphs 
showing the contraction to linopirdine (1 and 3 µmol/L) of renal 
arteries incubated for 16 h with vehicle (control, black bars) or R+M 
(white bars) in wire-myography experiments. Data are expressed as 
mean±SEM and shown as percentage of the initial contraction to 
60 mmol/L KCl. *P<0.05, **P<0.01; N=10 per experimental group. 
B, bar graphs showing the effects of methoxamine (3 µmol/L) in 
the presence of dimethyl sulfoxide (DMSO; vehicle, black bars), 3 
µmol/L linopirdine (Lino, white bars) or 1 µmol/L HMR1556 (gray 
bars) on isometric tension recordings of renal arteries incubated 
for 16 h with vehicle (control) or R+M. Data are expressed as 
mean±SEM and shown as percentage of the contraction to 30 
µmol/L methoxamine. ***P<0.001; ns=not significant; N=10 per 
experimental group.
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contractile responses to methoxamine concurrent with 
SMIT1 regulating arterial contractility. These effects do 
not appear to be primarily mediated by increased avail-
ability of intracellular myo-inositol as administration of 
myo-inositol alone did not mimic the effect of raffinose, 
and blockade of SMIT1 transport with phlorizin did not 
prevent the effects on arterial contractility.
SMIT1 Induces Vasorelaxation Through the 
Activation of Heteromeric Kv7.4–Kv7.5 Channels
Raffinose plus inositol inhibited contractions produced by 
lower concentration of K+ (≤40 mmol/L) but not higher 
concentrations consistent with an effect involving K+ 
channels. Opening of K+ channels hyperpolarizes the cell 
membrane potential thus reducing the activation of volt-
age-gated calcium channels and the consequent influx 
of calcium ions that is necessary for VSMCs contrac-
tion. VSMCs express a wide range of K+ channels that 
regulate arterial contractility,36,37 but considerable evi-
dence have been accumulated for a key role of Kv7.4/7.5 
channels in the regulation of basal arterial diameter and 
also the active response to receptor agonists.38 Thus, the 
pan-Kv7 blockers linopirdine and XE991 contract most 
arteries, whereas Kv7.1-specific blockers like HMR1556 
do not show a clear effect on vascular tone.12 Impairment 
Figure 6. Interaction of SMIT1 (sodium:myo-inositol transporter 1) with vascular Kv7 channels.
A, Proximity Ligation Assays (PLAs) showing the interaction of SMIT1 with Kv7.4 and Kv7.5 in vascular smooth muscle cells (VSMCs) isolated 
from renal and mesenteric arteries. The insets show a brightfield image of the cell. Nuclei (DAPI staining, blue) are also shown. Scale bar=5 
µm. B, Bar graphs showing the interactions of Kv7.4, Kv7.5, and SMIT1 with Kv2.1 and TRPC1 (transient receptor potential C1 channel) 
in VSMCs isolated from renal arteries incubated for 16 h with vehicle (control, black bars) or 150 mmol/L raffinose plus 1 mmol/L myo-
inositol (raffinose plus myo-inositol [R+M], white bars). Data represent the mean number of PLA signals per midcell xy section, expressed as 
mean±SEM. n=26–36 cells from 3 to 4 rats (N=3–4) per experimental point in 3–4 sessions. *P<0.05 vs respective controls. C, Bar graphs 
showing the interaction between Kv7.4-SMIT1, Kv7.5-SMIT1, and Kv7.4–Kv7.5 in renal VSMCs. Arteries were incubated with a scrambled 
morpholino (CTL-mor, black bars), a morpholino targeting Kv7.4 (Q4-mor, white bars), or a morpholino against Kv7.5 (Q5-mor, gray bars). Data 
represent the mean number of PLA signals per midcell xy section, expressed as mean±SEM. n=26–36 cells from 3 to 4 rats (N=3–4) per 
experimental point in 3 to 4 sessions. *P<0.05 vs respective controls (CTL-mor).
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of Kv7.4 function and expression have been observed in 
2 animal models of hypertension such as spontaneously 
hypertensive rats and angiotensin II–infused mice,33,39,40 
and trafficking of Kv7.4 subunits to the plasma membrane 
is altered upon stimulation with angiotensin II.24 Reduc-
tion of Kv7 function has also been observed in coronary 
arteries exposed to high glucose.41 Evidence from func-
tional and molecular studies have highlighted that Kv7.4 
and Kv7.5 form a heteromeric channel that is the main 
Kv7 species in VSMCs,42,43 with the participation of the 
accessory subunit KCNE4.35In the present study, knock-
down of SMIT1 attenuated the anticontractile effect of 
the Kv7.2–Kv7.5 specific activator ML213 but did not 
alter the effectiveness of activators of Kv7.1 (RL-3), BKCa 
(NS11021) or KATP (levcromakalim). The anticontrac-
tile effect of increasing SMIT1 levels was prevented by 
linopirdine but not the Kv7.1 specific blocker HMR1556 
nor tertiapin Q, a blocker of PIP2-sensitive GIRK chan-
nels. A role for Kv7.4 and 7.5 was consolidated by the use 
of morpholinos targeting Kv7.4 and Kv7.5 that abrogated 
the inhibitory effect of raising raffinose plus myo-inositol. 
Interestingly, the effects of ML213 were not potentiated 
after raffinose and myo-inositol incubation. A possible 
explanation is that overexpression of SMIT1 heightened 
the activity of Kv7.4/Kv7.5 sufficiently to negate the 
stimulatory effect of Kv7 activators. The fact that linopir-
dine was less able to contract resting arteries incubated 
with raffinose and myo-inositol supports this hypothesis, 
although it is possible that other mechanisms involved in 
arterial contraction might be affected by the increased 
expression of SMIT1.
A crucial role for Kv7 channels was corroborated by 
patch-clamp experiments showing that incubation with 
raffinose and myo-inositol increased the amplitude 
of Kv7 currents (XE991-sensitive) in renal VSMCs. 
Interestingly, when we recorded the effects of SMIT1 
on Kv7.4/Kv7.5 currents in heterologous systems, we 
observed only a trend to increase voltage-sensitivity of 
the Kv7.4/Kv7.5 channels that was quantitatively similar 
to that induced by SMIT1 on Kv7.2/Kv7.3 heteromeric 
channels (≈7 mV),14 but we were not able to show that 
overexpression of SMIT1 alone directly affected the cur-
rent amplitude of heteromeric Kv7.4/Kv7.5 channels. The 
discrepancy between patch-clamp data from VSMCs and 
CHO cells may reflect a different molecular architecture 
of the Kv7.4/Kv7.5 channels in the CHO cells compared 
with arterial smooth muscle cells. In particular, the ancil-
lary subunit KCNE4, which our PLA experiments show, 
interacts with SMIT1 in VSMCs, coassembles with Kv7 
channels and alters their function.35 Because KCNE 
subunits modulate the binding of SMIT1 to Kv7.2,14 the 
possibility exists that the lack of effect of SMIT1 over-
expression in CHO cells was due to the absence of 
KCNE4 subunits that could modify SMIT1 interaction 
with the Kv7.4/Kv7.5 channels. Alternatively, the relative 
increase in SMIT1 with respect to Kv7 channels in CHO 
Figure 7. Effects of SMIT1 (sodium:myo-inositol transporter 
1) on Kv7.4/Kv7.5-mediated currents.
A, Mean current-voltage relationship in Chinese Hamster Ovary 
cells transfected with plasmids encoding for Kv7.4 and Kv7.5 plus a 
GFP-encoding plasmid (black line) or a plasmid encoding for SMIT1 
(gray line). Data are expressed as mean±SEM. n=8 per experimental 
group. B, representative traces showing XE-991 sensitive currents 
in vascular smooth muscle cells (VSMCs) isolated from renal 
arteries incubated for 16 h with vehicle (control, black traces) or 150 
mmol/L raffinose plus 1 mmol/L myo-inositol (raffinose plus myo-
inositol [R+M], gray traces). C, Mean current-voltage relationship in 
VSMCs isolated from renal arteries incubated for 16 h with vehicle 
(control, black line) or 150 mmol/L raffinose plus 1 mmol/L myo-
inositol (R+M, gray line). Data are expressed as mean±SEM. n=7 
cells for control and 8 cells for R+M, obtained from 8 animals in 8 
experimental sessions. *P<0.05; **P<0.01; ***P<0.001 vs control.
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cells is likely to be very different than the situation in 
smooth muscle cells following raffinose-induced SMIT1 
increase. Moreover, we cannot rule out the possibility that 
additional proteins known to interact with Kv7 channels12 
might mediate the functional consequences exerted by 
SMIT1 on Kv7 channels in arteries. Regardless, modu-
lation of SMIT1 protein levels has a marked impact on 
renal artery reactivity mediated through an increase in 
Kv7.4/7.5 activity.
Overexpression of SMIT1 potentiates Kv7.1, Kv7.2, 
and Kv7.3 channels activity by a physical interaction with 
the channel pore that induces a conformational change 
affecting the gating and pharmacological properties of 
Kv7 subunits in the absence of myo-inositol14 and via 
a PIP2-dependent mechanism that requires extracellu-
lar inositol.16,17 Our data suggest that both the physical 
interaction of SMIT1 and Kv7 channels and localized 
increase in PIP2 via enhanced myo-inositol transport 
play a role in the regulation of Kv7.4/Kv7.5 channels by 
SMIT1 in the vasculature. Thus, phlorizin, which prevents 
SMIT1 transport function and wortmannin, that depletes 
PIP2, only partially prevented the effects on contractility 
exerted by the incubation with raffinose plus myo-inosi-
tol. Furthermore, raffinose alone altered arterial contrac-
tility. Synergistic interplay of PIP2 with other regulators of 
Kv7 channels, such as G-protein βγ subunits, have been 
previously shown to potentiate Kv7.4 currents44; there-
fore, the possibility exists that the interaction of SMIT1 
with Kv7.4/Kv7.5 induces a conformational change of the 
channel that facilitates the binding of PIP2.
SMIT1 Resides in Close Proximity to Kv7.4 and 
Kv7.5
Physical interaction of SMIT1 with Kv7.1, Kv7.2, and 
Kv7.3 have been shown in overexpression systems, neu-
rons, and choroid plexus epithelium, where they recipro-
cally regulate their function.8,16,17 Our data showed that 
in VSMCs SMIT1 resided in close proximity (<40 nm) 
with both Kv7.4 and Kv7.5 subunits, as well as the acces-
sory subunit KCNE4. Interestingly, PLA also showed 
that SMIT1 overexpression selectively increased the 
interaction between SMIT1 and Kv7.4/Kv7.5, without 
affecting the interaction of these proteins with other 
molecular partners, such as Kv2.1 or TRPC1. In par-
ticular, our PLA data show a preferential interaction of 
SMIT1 with heteromeric Kv7.4/Kv7.5 channels because 
knockdown of either Kv7.4 or Kv7.5 reduced the interac-
tion of SMIT1 with both Kv7 subunits, consistent with 
the reduction of Kv7.4–Kv7.5 heteromers induced by 
Kv7 subunits silencing. The preferential interaction of 
SMIT1 with the heteromeric channels is also suggested 
by PLA data from overexpression system showing that 
SMIT1-Kv7.4 interaction occurred only when both Kv7 
subunits were expressed in CHO cells. These data are 
consistent with previous evidence showing that SMIT1 
neither coimmunoprecipitated with Kv7.4 nor affected 
the currents mediated by Kv7.4 homomeric channels.8 
Assembly of heteromeric Kv7 channels occurs very 
early during protein trafficking to the plasma mem-
brane and is responsible for increased channel insertion 
and enhanced Kv7-mediated currents.45,46 PLA data in 
overexpression system also suggest that the molecular 
determinants responsible for this interaction are local-
ized within Kv7.5 because only the Kv7.5 subunit was 
able to interact with SMIT1 in homomeric conforma-
tion, although the possibility exists that SMIT1 binds a 
complex region resulting from the heteromeric assembly 
of Kv7.4 and Kv7.5 subunits. Interestingly, interaction of 
Kv7.5 with SMIT1 seemed to be reduced when Kv7.4 and 
Kv7.5 were coexpressed in CHO cells. A recent study 
identified the pore region of Kv7.2 as necessary and suf-
ficient for SMIT1 binding to this subunit. However, the 
authors suggested that the docking site for SMIT1 on 
Kv7.2 was large enough to allow further binding of the 
ancillary KCNE subunits which could, in turn, modulate 
SMIT1 interaction.14 Therefore, the possibility exists that 
a complex interaction between Kv7.4, Kv7.5, and KCNE4 
might occur in VSMCs, possibly increasing the interac-
tion of SMIT1 with Kv7.4/Kv7.5 in native cells. Further 
studies are needed to identify the molecular determi-
nants of SMIT1 binding on vascular Kv7 channels and 
clarify the stoichiometry of this interaction. Irrespective 
of these issues, these data are, to our knowledge, the 
first evidence of the interaction of an organic osmolyte 
transporter and a potassium channel in the vasculature.
Conclusions
Crosstalk between members of the transporters- and ion 
channels families has been unveiled recently, highlighting 
a high degree of functional and physical interaction that 
has led to the creation of the term chansporter.15 Here, 
we describe for the first time a functional and molecu-
lar interaction between a myo-inositol transporter and a 
potassium channels in the vasculature that affects arte-
rial contractility. Such interaction might provide an expla-
nation for the changes in vascular reactivity observed 
in hyperosmolarity, a condition occurring in pathologies, 
such as diabetes mellitus.
In conclusion, our data unveil a novel mechanism 
regulating arterial reactivity and highlight a new potential 
strategy in the treatment of vascular disease.
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